SUPERNUS PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Available-for-sale Securities, Amortized Cost Basis of $174.24 million as of 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-03-01
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $174.24M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $155.71M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $135.86M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $116.88M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2017-12-31 | $174.24M 10-K · filed 2018-03-01 | |
| 2017-09-30 | $155.71M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $135.86M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $116.88M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $99.49M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $92.70M 10-Q · filed 2017-01-20 | |
| 2016-06-30 | $91.32M 10-Q/A · filed 2017-01-23 | |
| 2016-03-31 | $94.05M 10-Q/A · filed 2017-01-20 | |
| 2015-12-31 | $84.19M 10-K · filed 2017-03-16 | $83.53M 10-K · filed 2016-03-09 |
| 2015-09-30 | $76.14M 10-Q/A · filed 2017-01-20 | $75.48M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $70.97M 10-Q/A · filed 2017-01-23 | $70.32M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $67.06M 10-Q/A · filed 2017-01-20 | $66.41M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $57.91M 10-Q/A · filed 2017-01-20 | |
| 2014-09-30 | $50.58M 10-Q/A · filed 2017-01-20 | |
| 2014-06-30 | $50.77M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $58.28M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $57.97M 10-K · filed 2015-03-12 | $48.26M 10-Q · filed 2013-11-13 |
| 2013-09-30 | $79.59M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $85.03M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $51.07M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $48.26M 10-K · filed 2014-03-21 | |
| 2012-06-30 | $48.26M 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |